Cathy Zhou

2.7k total citations · 4 hit papers
42 papers, 1.5k citations indexed

About

Cathy Zhou is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Cathy Zhou has authored 42 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Genetics, 27 papers in Pathology and Forensic Medicine and 17 papers in Hematology. Recurrent topics in Cathy Zhou's work include Chronic Lymphocytic Leukemia Research (41 papers), Lymphoma Diagnosis and Treatment (27 papers) and Chronic Myeloid Leukemia Treatments (16 papers). Cathy Zhou is often cited by papers focused on Chronic Lymphocytic Leukemia Research (41 papers), Lymphoma Diagnosis and Treatment (27 papers) and Chronic Myeloid Leukemia Treatments (16 papers). Cathy Zhou collaborates with scholars based in United States, Italy and Australia. Cathy Zhou's co-authors include Danelle F. James, William G. Wierda, Jan A. Burger, Steven Coutré, Alessandra Tedeschi, Carol Moreno, Susan O’Brien, John C. Byrd, Jeffrey A. Jones and Nyla A. Heerema and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Cathy Zhou

40 papers receiving 1.5k citations

Hit Papers

Three-year follow-up of treatment-naïve and previously tr... 2015 2026 2018 2022 2015 2018 2022 2022 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
    2015 484 citations John C. Byrd, Richard R. Furman et al. Blood profile →
  2. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
    2018 380 citations Carol Moreno, Richard Greil et al. The Lancet Oncology profile →
  3. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia 
    2022 146 citations Paul M. Barr, Carolyn Owen et al. Blood Advances profile →
  4. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
    2022 124 citations Constantine S. Tam, John N. Allan et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cathy Zhou United States 13 1.4k 1.2k 501 450 189 42 1.5k
Kerry A. Rogers United States 20 1.1k 0.8× 886 0.8× 410 0.8× 420 0.9× 257 1.4× 124 1.4k
Martin Šimkovič Czechia 12 954 0.7× 797 0.7× 340 0.7× 282 0.6× 160 0.8× 57 1.1k
Liana Gercheva Bulgaria 15 707 0.5× 417 0.4× 209 0.4× 765 1.7× 194 1.0× 46 1.3k
Olga Samoilova Russia 9 574 0.4× 634 0.5× 179 0.4× 254 0.6× 388 2.1× 20 912
Rachel L. Sargent United States 15 471 0.3× 434 0.4× 139 0.3× 240 0.5× 177 0.9× 39 851
Paul Moreton United Kingdom 12 712 0.5× 649 0.6× 425 0.8× 160 0.4× 104 0.6× 21 872
Leanne Holes United States 18 799 0.6× 565 0.5× 229 0.5× 256 0.6× 135 0.7× 37 911
Anita Szőke United States 10 1.0k 0.7× 442 0.4× 191 0.4× 536 1.2× 128 0.7× 25 1.1k
Sasanka M. Handunnetti Australia 12 555 0.4× 498 0.4× 149 0.3× 172 0.4× 293 1.6× 25 739
Nedjad Losic United States 10 547 0.4× 551 0.5× 304 0.6× 168 0.4× 284 1.5× 23 871

Countries citing papers authored by Cathy Zhou

Since Specialization
Citations

This map shows the geographic impact of Cathy Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cathy Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cathy Zhou more than expected).

Fields of papers citing papers by Cathy Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cathy Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cathy Zhou. The network helps show where Cathy Zhou may publish in the future.

Co-authorship network of co-authors of Cathy Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Cathy Zhou. A scholar is included among the top collaborators of Cathy Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cathy Zhou. Cathy Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burger, Jan A., Paul M. Barr, Tadeusz Robak, et al.. (2025). Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. Blood. 146(18). 2168–2176. 5 indexed citations
2.
Burger, Jan A., Paul M. Barr, Tadeusz Robak, et al.. (2024). CLL-076 Final Analysis of the RESONATE-2 Study: up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 24. S342–S343. 4 indexed citations
3.
4.
Burger, Jan A., Paul M. Barr, Tadeusz Robak, et al.. (2024). Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 24. S179–S179. 5 indexed citations
5.
6.
Ghia, Paolo, John N. Allan, Tanya Siddiqi, et al.. (2023). FIXED‐DURATION IBRUTINIB + VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4‐Y FOLLOW‐UP FROM THE FD COHORT OF THE PHASE 2 CAPTIVATE STUDY. Hematological Oncology. 41(S2). 238–239. 1 indexed citations
7.
Moreno, Carol, Constantine S. Tam, Andrew Grigg, et al.. (2023). Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. Blood Advances. 7(18). 5294–5303. 10 indexed citations
8.
Barr, Paul M., Alessandra Tedeschi, William G. Wierda, et al.. (2022). Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts. Clinical Cancer Research. 28(20). 4385–4391. 6 indexed citations
9.
Barr, Paul M., Carolyn Owen, Tadeusz Robak, et al.. (2022). Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia . Blood Advances. 6(11). 3440–3450. 146 indexed citations breakdown →
10.
Tam, Constantine S., John N. Allan, Tanya Siddiqi, et al.. (2022). Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 139(22). 3278–3289. 124 indexed citations breakdown →
11.
12.
13.
14.
Greil, Richard, Alessandra Tedeschi, Carol Moreno, et al.. (2021). Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. Annals of Hematology. 100(7). 1733–1742. 9 indexed citations
15.
16.
Jones, Jeffrey A., Anthony R. Mato, Steven Coutré, et al.. (2018). Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. British Journal of Haematology. 182(4). 504–512. 32 indexed citations
17.
Moreno, Carol, Richard Greil, Fatih Demırkan, et al.. (2018). Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 20(1). 43–56. 380 indexed citations breakdown →
18.
Coutré, Steven, Richard R. Furman, Ian W. Flinn, et al.. (2017). Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Cancer Research. 23(5). 1149–1155. 47 indexed citations
19.
Kipps, Thomas J., Tadeusz Robak, Alessandra Tedeschi, et al.. (2016). Improvement in hematologic function, disease burden/symptoms with ibrutinib in older treatment-naive (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2 (TM). Journal of the American Geriatrics Society. 64. 1 indexed citations
20.
O’Brien, Susan, Steven Coutré, Richard R. Furman, et al.. (2015). Durable Responses Including Complete Responses in CLL Following Long Term Treatment With Single-agent Ibrutinib 420 mg. Clinical Lymphoma Myeloma & Leukemia. 15. S23–S23. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kerry A. Rogers Breakdown of academic impact, for papers by Martin Šimkovič Breakdown of academic impact, for papers by Liana Gercheva Breakdown of academic impact, for papers by Olga Samoilova Breakdown of academic impact, for papers by Rachel L. Sargent Breakdown of academic impact, for papers by Paul Moreton Breakdown of academic impact, for papers by Leanne Holes Breakdown of academic impact, for papers by Anita Szőke Breakdown of academic impact, for papers by Sasanka M. Handunnetti Breakdown of academic impact, for papers by Nedjad Losic
Rankless by CCL
2026